12 results
Primary:The primary objective of this study is to determine whether DMF taken over 12 months is effective in reducing MS-related fatigue, as measured by mean changes in the Fatigue Scale for Motor and Cognitive Functions (FSMC), in subjects with…
The main objective of this study is to depict microglial activation behind a closed BBB in vivo and possibly establish an imaging marker of fast clinical progression, we will aim at visualizing microglial activity in vivo in cortical and hippocampal…
To identify (clinical) features of MMN patients that predict a poor clinical disease course. Moge agressive IVIg regimen can be established is this subgroup to maintain functional status of the patient. To find domains in quality of life in MMN…
Primary objective: To evaluate the long-term safety of IgPro20.Secondary objectives: * To evaluate the long-term safety of IgPro20 by dose. * To evaluate the efficacy of IgPro20.Exploratory objectives:* To evaluate health-related quality of life (…
The main objective of the proposed study is to investigate whether the disproportionally strong clinical effects of fingolimod in RRMS can be explained by enhanced functional brain adaptation and whether enhanced functional adaptation is sustained…
Evaluate the added value of new MRI and US techniques for the diagnosis of neuromuscular disorders such as MMN and CIDP and the MMN-mimic fSMA.
(1) to establish the neuropsychiatric and personality status (symptoms and impairments) (2) to assess the possible determinants of these symptoms and impairments and (3) to examine the impact of these symptoms and impairments on daily life…
The objective of this study is to assess the distribution of infusion associated reactions (IARs) by severity grade when Lemtrada is administered to RRMS patients who will be medicated according to specified algorithm designed to manage infusion…
Immune regulation by dimethylfumarate (DMF) in patients with relapsing Remitting Multiple Sclerosis.
Primary objective: * Increases treatment with DMF the ability of Tregs to inhibit in relapsing-remitting MS patients? Proliferation of conventional T cells * Provides treatment with DMF to an increase in the number of nTreg (Foxp3 expression) or…
The objectives of this study are to assess the efficacy, safety, and tolerability of a once daily oral dose of laquinimod (0.6 or 1.5 mg) compared to placebo in PPMS patients.
To evaluate the long-term safety and efficacy of alemtuzumab, for patients already treated with this medicine in preceding clinical trials (CARE-MS I, CARE-MS II and CAMMS03409).
The aim of the proposed study is to obtain insight into the temporal dynamics of functional reorganization and cognition, and to assess the effect of cognitive rehabilitation on this adaptive mechanism and cognitive functioning.